Endo, Penwest In Royalty Dispute Over Opana ER
This article was originally published in The Pink Sheet Daily
Executive Summary
Partners enter mediation to resolve issues over responsibility for marketing costs associated with the launch of the pain drug.
You may also be interested in...
Endo Agrees To $90 Million In Milestone Payments For Opana ER
Firm also commits to a tiered royalty schedule to resolve dispute with development partner Penwest.
Endo Agrees To $90 Million In Milestone Payments For Opana ER
Firm also commits to a tiered royalty schedule to resolve dispute with development partner Penwest.
Opana Uptake Slower Than Anticipated, But Script Growth Is On The Rise
Scripts for Endo's oral oxymorphone reached 1,137 the week of Sept. 29, according to IMS weekly trend data.